Lancet Diabetes & Endocrinology

Article	Citations
Paisan Ruamviboonsuk: saving sight in Thailand	901
Vitamin D supplementation and mortality	779
Empagliflozin in adults hospitalised with COVID-19: a (null) hypothesis for RECOVERY	488
Madelung's disease in a rare 14th century Franco-Flemish woolen tapestry	429
Metabolic non-communicable diseases in India: time to act	398
Postsurgical radioiodine ablation in low-risk differentiated thyroid cancer	387
Ashley Grossman: finding a calling in neuroendocrinology	382
Mark Atkinson: bringing two worlds together	365
Vitamin D to prevent acute respiratory infections	344
Action framework on healthy food: a way forward for the public sector	320
Fetal growth patterns as early markers of fetal programming	306
Perfluoroalkyl and polyfluoroalkyl substances: the price of forever chemicals	299
Implications of technology guidelines for low-income and middle-income countries	282
Diabetes and the WHO Model List of Essential Medicines	261
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions	252
Dissection of type 2 diabetes: a genetic perspective	251
The human factor	226
Insulin for all: a hope yet to be realised	218
May Ng: a lifetime commitment to children	216
A framework for improving diabetes care in humanitarian emergencies	216
Dulaglutide for erectile dysfunction in type 2 diabetes	206
Tackling childhood obesity in low-socioeconomic status communities: what is the next step?	185
A community-based, multi-level, multi-setting, multi-component intervention to reduce weight gain among low socioeconomic status Latinx children with overweight or obesity: The Stanford GOALS randomis	177
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial	176
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel	176

Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study	175
New metrics to support diabetes education and advocacy	168
Impact of COVID-19 on diagnoses, monitoring, and mortality in people with type 2 diabetes in the UK	160
Data processing in the DMagic cluster randomised controlled trial	159
Youth-onset type 2 diabetes among First Nations young people in northern Australia: a retrospective, cross-sectional study	157
Associations between reductions in routine care delivery and non-COVID-19-related mortality in people with diabetes in England during the COVID-19 pandemic: a population-based parallel cohort study	152
Estimating the total incidence of type 1 diabetes in children and adolescents aged 0–19 years from 1990 to 2050: a global simulation-based analysis	151
Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial	150
Trends in leading causes of hospitalisation of adults with diabetes in England from 2003 to 2018: an epidemiological analysis of linked primary care records	146
Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study	140
Cardiovascular morbidity and mortality in patients in Wales, UK with resistance to thyroid hormone β (RTHβ): a linked-record cohort study	138
Current insights and emerging trends in early-onset type 2 diabetes	132
PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial	119
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial	119
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial	116
Sex steroids and the female brain across the lifespan: insights into risk of depression and Alzheimer's disease	116
Challenges in implementing nationwide epidemiological studies on metabolic non-communicable diseases in low-income and middle-income countries	112
Global diabetes incidence trends in young adults	111
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, p	110
Association of age with gaps in diabetes-related care and hospitalisations from childhood to young adulthood in Quebec, Canada: a cohort study	103
The growing global burden of thyroid cancer overdiagnosis	102
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis	102
Semaglutide for obesity: four STEPs forward, but more to come	101
Effect of the COVID-19 pandemic on body weight in people at high risk of type 2 diabetes referred to the English NHS Diabetes Prevention Programme	99
Diabetes and the WHO Model List of Essential Medicines	95
Big babies, small babies: metformin exposure in pregnancy	94
Milestone achievement for global access to blood glucose meters and test strips	93
People with type 1 diabetes and chronic kidney disease urgently need new therapies: a call for action	93
South Africa to produce insulin for Africa in 2024	91
Reducing sodium intake: step-by-step targets yield success	87
What's preventing us from curbing the obesity crisis?	85
Thought for food: a Cushing's syndrome enigma explained	82
Progress in diabetes prevention or epidemiology—or both, or neither?	81
Newer antidiabetic agents: at what price will they be cost effective?	81
The growing clinical effect of SGLT2 inhibitors	80
Mendelian randomisation and vitamin D: the importance of model assumptions	78
Targeting RET-mutated thyroid and lung cancer in the personalised medicine era	78
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes – Authors' reply	77
Long-term trial outcomes of Roux-en-Y gastric bypass and one anastomosis gastric bypass: tipping the scale	76
Hot topics on insulin access: the issue of thermostability	76
Banning diabetes blanket bans	76
Gender disparities in publishing: from words to actions	75
Anand Hardikar: a scientific nomad searching for the truth	75
The food system: hunger for change	73
Post-exercise recovery for the endurance athlete with type 1 diabetes: a consensus statement	73
What's in a decade?	66
The effect of monthly vitamin D supplementation on fractures: a tertiary outcome from the population-based, double-blind, randomised, placebo-controlled D-Health trial	66
Metastases to the thyroid gland: how does this affect cytohistological diagnoses?	66
The relevance of T3 in the management of hypothyroidism	66
Call for prospective studies of continuous glucose monitoring to define the glycaemic response to bariatric surgery	64

GLP1 receptor agonists: from antihyperglycaemic to cardiovascular drugs	63
A compass for navigating the perils of hypertriglyceridaemia	59
Better testing and labelling of drugs for people with obesity	59
GLP-1 analogue therapy for obesity in people from Asia	58
Impact of BMI on COVID-19 vaccine effectiveness	58
Iodine deficiency in Europe: vigilance and action required	58
Food additive emulsifiers and risk of type 2 diabetes	57
Evaluation of a type 2 diabetes remission programme	56
Evaluation of a type 2 diabetes remission programme – Authors' reply	54
Setmelanotide for the treatment of severe early-childhood genetic obesity	53
Tirzepatide adds hepatoprotection to its armoury	53
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial	53
Sleep: a neglected public health issue	52
Direct-to-consumer services: improving access to care for people with diabetes and obesity	52
Tight versus liberal blood-glucose control in the intensive care unit: special considerations for patients with diabetes	50
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes	49
Glucose intolerance in pregnancy and risk of early-onset type 2 diabetes: a population-based cohort study	48
Singapore's “War on Diabetes”	45
Childhood cancer survival: a gap in need of closing	45
Setmelanotide: new promise for the treatment of hypothalamic obesity?	44
Obesity in people living with type 1 diabetes	44
World Health Assembly ratifies first global diabetes targets	44
Forecasting therapeutic responses by albuminuria and eGFR slope during the DAPA-CKD trial	43
Measuring serum testosterone in women	42
SGLT2 inhibitors in clinical practice	42
Associations of the glycaemic index and the glycaemic load with risk of type 2 diabetes in 127 594 people from 20 countries (PURE): a prospective cohort study	40
Adrenal myelolipomas	40
National UK guidelines for the management of paediatric craniopharyngioma	39
Data-driven subgroups of type 2 diabetes, metabolic response, and renal risk profile after bariatric surgery: a retrospective cohort study	39
Risk and course of SARS-CoV-2 infection in patients treated for hypothyroidism and hyperthyroidism	39
Osteopenia: a key target for fracture prevention	39
Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17)	38
Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials	38
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials	37
Management of thyroid nodules	37
Osteoporosis in men	36
Obesity in the USA: diet and lifestyle key to prevention	36
Nutritional intake and bone health	36
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, dou	35
Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study	34
Correction to Lancet Diabetes Endocrinol 2023; 11: 785–87	34
An anti-PCSK9 pill a day to keep cholesterol away: next steps?	34
Correction to Lancet Diabetes Endocrinol 2021; 9: 743–54	33
Correction to Lancet Diabetes Endocrinol 2023; 11: 942–54	33
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes	32
Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study	32
Disease modifying therapies in diabetes and endocrinology	32
Correction to Lancet Diabetes Endocrinol 2022; published online Sept 29. https://doi.org/10.1016/S2213-8587(22)00252-2	32
Correction to Lancet Diabetes Endocrinol 2022; 10: 741–60	32
Correction to Lancet Diabetes Endocrinol 2022; 10: 489–98	32
Consensus on diagnosis and management of Cushing's disease: a guideline update	31
Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open‑label, multinational, randomised, controlled	31
Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials	31
C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis	30
Lifetime risk, life expectancy, and years of life lost to type 2 diabetes in 23 high-income jurisdictions: a multinational, population-based study	30
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality	29
Correction to Lancet Diabetes Endocrinol 2022; 10: 58–74	29
Association of glycaemic index and glycaemic load with type 2 diabetes in the PURE study – Authors' reply	29
Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial	29
Type 1 diabetes screening: need for ethical, equity, and health systems perspective	28
Prediabetes: much more than just a risk factor	28
Automated insulin delivery during the first 6 months postpartum (AiDAPT): a prespecified extension study	28
The potential role for artificial intelligence in fracture risk prediction	28
Protein-binding therapy: a new approach to lower cholesterol	28
Hybrid closed-loop insulin therapy and risk of severe hypoglycaemia and diabetic ketoacidosis in young people (aged 2–20 years) with type 1 diabetes: a population-based study	27
Correction to Lancet Diabetes Endocrinol 2025; 13: 221–62	26
Implementing digital systems in diabetes care in low-income and middle-income countries: successes and challenges	26
Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunction	26
Gestational diabetes in Australia: navigating a tsunami	26
Diabetes and the WHO Model List of Essential Medicines	26
Impact of bodyweight loss on type 2 diabetes remission: a systematic review and meta-regression analysis of randomised controlled trials	26
Nutrition-related health taxes: setting expectations	26
Lorenz Hofbauer: connecting the unexpected	25
Stigma in type 1 diabetes: a global problem	25
Jennifer Manne-Goehler: at the crossroads of pandemics	25
Sylvia Kehlenbrink: facing the extremes	25
Challenges in the treatment of young people with type 2 diabetes	25
Global patterns and trends in incidence and mortality of thyroid cancer in children and adolescents: a population-based study	24
Long-term population-based trends in the incidence of cardiovascular disease in individuals with type 1 diabetes from Finland: a retrospective, nationwide, cohort study	24
Identifying adults at high-risk for change in weight and BMI in England: a longitudinal, large-scale, population-based cohort study using electronic health records	24

National registries as a catalyst to development of diabetes care in low-income and middle-income countries	24
Revisiting osteoporosis guidelines	24
Principles for virtual health care to deliver real equity in diabetes	24
Scientific medical conferences can be easily modified to improve female inclusion: a prospective study	23
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised,	23
Glycaemic management in diabetes: old and new approaches	23
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial – Authors' reply	22
Lipoprotein(a) and carotid intima-media thickness in children with familial hypercholesterolaemia in the Netherlands: a 20-year follow-up study	22
Risk of second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma: a retrospective, multicentre, cohort study of 3679 patients with long-term imaging surveillance	22
Impact of the COVID-19 pandemic on transgender and gender diverse health care	22
Precision medicine of obesity as an integral part of type 2 diabetes management – past, present, and future	22
Understanding diabetes heterogeneity: key steps towards precision medicine in diabetes	22
Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial	22
Behind the scenes: epigenetic mechanisms rule the roost in pubertal timing	21
A roadmap for integrating mental health and diabetes services	21
New clarity for managing statin intolerance in diabetes	21
Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicent	21
Daily low-dose aspirin and incident type 2 diabetes in community-dwelling healthy older adults: a post-hoc analysis of efficacy and safety in the ASPREE randomised placebo-controlled trial	21
Association of BMI, lipid-lowering medication, and age with prevalence of type 2 diabetes in adults with heterozygous familial hypercholesterolaemia: a worldwide cross-sectional study	20
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial	20
The Human Insulin Thermal Solution project—a private sector initiative to address the thermostability of insulin	20
Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial	19
Retraction and republication—Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses	19
Perceptions of alternative methods of insulin storage: an ethical dilemma	19
Glycaemic index as part of the diabetes prevention strategy	19
Insulin thermostability in a real-world setting	19
The double burden of poor diets	18
Prioritising COVID-19 over everything: the unintended harm	18
The TRAVERSE trial: cardiovascular safety of testosterone therapy for older men	18
Out on a limb: living with diabetes in the Philippines during the pandemic	18
Black oesophagus in an adolescent with type 2 diabetes	18
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial	17
Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials	17
Dianna Magliano: at the forefront of change	17
Islet-after-kidney transplantation versus kidney alone in kidney transplant recipients with type 1 diabetes (KAIAK): a population-based target trial emulation in France	17
Improving health equity through data collection	17
Biodiversity and its double-edged role in the pathogenesis of type 1 diabetes	17
Jonathan Valabhji: from clinical practice to policy making and back	17
COP27 Climate Change Conference: urgent action needed for Africa and the world	16
Global thyroid estimates in 2020	16
Silver Bahendeka: the obligation to hope	16
Youth gender services: a new model for regional care	16
Rising diabetes diagnosis in long COVID	16
Can non-equilibrium thermodynamics explain skeletal muscle insulin resistance due to low mitochondrial content?	15
The role of nurses in diabetes care: challenges and opportunities	15
Food additive emulsifiers: a new risk factor for type 2 diabetes?	14
Metabolic non-communicable diseases in India: time to act – Authors' reply	14
Association between BMI and COVID-19 on hospital budgets	14
Type 1 diabetes: heterogeneity in heritability	14
Maria Fleseriu: driving excellence in pituitary care	14
Iodine status in Iran: from deficient to replete	14
Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis	13
Achieving replicable subphenotypes of adult-onset diabetes	13
Contribution of heterozygous PCSK1 variants to obesity and implications for precision medicine: a case-control study	13
The changing character of diabetes complications	13
Lebanon: insulin out of reach after subsidies lifted	13